Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03184558
Recruitment Status : Completed
First Posted : June 12, 2017
Last Update Posted : April 3, 2019
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
BerGenBio ASA

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : August 30, 2018
Actual Study Completion Date : August 30, 2018